Welcome
PharmaNeuroBoost (PNB) - founded in 2006 - is a biopharmaceutical
company dedicated to developing best in class CNS therapeutics. As
such, PNB is specialized in boosting current standard of care on major
psychiatric disorders with a high unmet medical need.
The two front-running proprietary projects (PNB01 and PNB02) are
targeted against major depression and schizophrenia, respectively.
The innovative concepts of PNB exploit the benefits of ‘boosting’
efficacy, based on a thorough mechanistic understanding of selective
receptor involvement and receptor interplay at the CNS level.
These assets are directed at large unmet medical needs and major
commercial markets.
Our drug candidates in different stages of clinical development, result
from discoveries made using our unique IP platform claiming the use
of high selective Serotonin 2A / Dopamine 4 receptor antagonists.
PNB’ Business Plan is oriented to collaboration with high value
partners for co-development and/or commercialization of our late
stage products.
company dedicated to developing best in class CNS therapeutics. As
such, PNB is specialized in boosting current standard of care on major
psychiatric disorders with a high unmet medical need.
The two front-running proprietary projects (PNB01 and PNB02) are
targeted against major depression and schizophrenia, respectively.
The innovative concepts of PNB exploit the benefits of ‘boosting’
efficacy, based on a thorough mechanistic understanding of selective
receptor involvement and receptor interplay at the CNS level.
These assets are directed at large unmet medical needs and major
commercial markets.
Our drug candidates in different stages of clinical development, result
from discoveries made using our unique IP platform claiming the use
of high selective Serotonin 2A / Dopamine 4 receptor antagonists.
PNB’ Business Plan is oriented to collaboration with high value
partners for co-development and/or commercialization of our late
stage products.
| © PharmaNeuroBoost 2010 - All Rights Reserved |
 |  |  |  |  |  |  |  |  |
| News Highlights |
June 28, 2010
Evidence for the selectivity of
low dose pipamperone for
5HT2A
June 28, 2010
PharmaNeuroBoost’s lead
product in major depression
receives IND approval from FDA